Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17605250 | 0.84 | EP300 (0.41) | RIPK1TDP1MEN1KMT2AGAA | |
| SCHEMBL17605248 | 0.84 | EP300 (0.41) | RIPK1TDP1MEN1KMT2AGAA | |
| SCHEMBL6417313 | 0.83 | TDP1 (0.49) | RIPK1TDP1MEN1KMT2ALIPE | |
| SCHEMBL22040832 | 0.79 | KMT2A (0.40) | RIPK1TDP1MEN1KMT2AGAA | |
| SCHEMBL17983939 | 0.76 | LMNA (0.46) | RIPK1TDP1MEN1KMT2AGAA | |
| SCHEMBL6413341 | 0.76 | TDP1 (0.59) | RIPK1TDP1MEN1KMT2AGABRA1 | |
| SCHEMBL2760548 | 0.74 | RIPK1 (0.60) | RIPK1TDP1MEN1KMT2ALIPE | |
| SCHEMBL6078000 | 0.72 | LMNA (0.55) | RIPK1TDP1MEN1KMT2ANSD2 | |
| SCHEMBL17606069 | 0.71 | ALDH1A1 (0.43) | MEN1KMT2AGAA | |
| SCHEMBL17606068 | 0.71 | ALDH1A1 (0.43) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889138-B1 | HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | RIPK1 4350/4885TDP1 1693/4885MEN1 330/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | RIPK1 4319/4885TDP1 1667/4885MEN1 310/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | RIPK1 4350/4885TDP1 1693/4885MEN1 330/4885 |
| US-20220087996-A1 | Histone acetylase p300 inhibitor and use thereof | EP300, HDAC1, HDAC11 | RIPK1 3111/4885TDP1 1516/4885MEN1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.